Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 32Central Nervous System Neoplasms 30Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 27Head and Neck Neoplasms 26Glioblastoma 25Leukemia 24Squamous Cell Carcinoma of Head and Neck 22Lymphoma 22Gliosarcoma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Sarcoma 17Astrocytoma 17Burkitt Lymphoma 14Pancreatic Neoplasms 13Rectal Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Uterine Cervical Neoplasms 11Neuroblastoma 11Lymphoma, Follicular 10Adenocarcinoma of Lung 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Acute 9Esophageal Neoplasms 9Brain Neoplasms 9Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Laryngeal Neoplasms 8Hodgkin Disease 8

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemoptysis × Radiotherapy × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡